Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Than Half Of Trials Conducted In South Korea Led By Pfizer

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The number of clinical trials Pfizer Korea conducted in South Korea last year rose sharply to 93 cases from 75 cases in 2007, a result of Pfizer's move to conduct more of its clinical trials in South Korea
Advertisement

Related Content

Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 1 of 2)
Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 1 of 2)
Japan's First CRO On How ICH Affects Clinical Trials in Japan: An Interview With CMIC Exec Moriaki Akasaki
Japan's First CRO On How ICH Affects Clinical Trials in Japan: An Interview With CMIC Exec Moriaki Akasaki
South Korean Government Moves To Produce Hospital Marketing Specialists To Raise Local Standards
South Korean Government Moves To Produce Hospital Marketing Specialists To Raise Local Standards
Korea Targets Biologics, Devices, Health Care Among Economic Growth Projects For Next Decade
Multinationals Step Up Clinical Trials In South Korea
Pfizer Plans R&D, Manufacturing Expansion In Asia
Pfizer Plans R&D, Manufacturing Expansion In Asia
Advertisement
UsernamePublicRestriction

Register

SC069806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel